GEHC — GE HealthCare Technologies Inc.

Post-Q2 2026 sentiment is constructive: orders grew 11.1%, book-to-bill hit 1.15, record backlog reached $23.9B, and management reaffirmed guidance. Several banks raised targets (Wells Fargo to $85, Evercore to $84, BTIG at $79) and consensus is Buy. The price action is less hot—neutral RSI and below the 200-day—so sentiment is bullish but not frothy.

Revenue is in a mid-single-digit growth channel with one ugly quarter: Q2 2026 revenue $5.30B (+5.8% YoY), Q1 2026 $5.13B (+7.4% YoY), Q3 2025 $5.14B (+5.8% YoY), but Q4 2025 fell -12.1% YoY to $4.67B. Operating margins are stable-to-better: Q2 2026 operating margin 14.0% vs 13.1% a year ago, and TTM operating margin is 12.7%. Reported EPS is noisy—Q4 2025 EPS collapsed to $0.38 from $1.57, likely one-off, while Q2 2026 EPS rebounded to $1.24—so the underlying revenue/operating trend is stable, but cash conversion is weak: Q2 2026 OCF was -$517M.

On trailing numbers GEHC is not cheap: 20.8x TTM EPS of $3.51, above the 5-year average 17.5x; P/S of 1.62x is roughly in line with the 5-year average 1.68x. On forward numbers it looks more reasonable: at consensus next-FY EPS of $4.93, the forward P/E is only ~14.7x. The negative PEG is an artifact of the one-off earnings drag in Q4 2025, not a useful signal. Overall: fair on forward, slightly rich on trailing, with no clear valuation cushion.

The $72.48 price is betting on an earnings recovery from TTM $3.51 to consensus $4.93 (+40%). If that materializes, the multiple is undemanding at ~14.7x forward; if estimates slip toward $4.00, the stock is paying ~18x with little margin of safety. The market is not pricing in unproven new growth—it is pricing in normalization that the trailing financials have yet to show, especially in FCF.

As of 2026-08-27, RSI was 55.9 (neutral), price was +0.1% vs the 20-day SMA, +7.6% vs the 50-day SMA, and -0.5% vs the 200-day SMA. This is a range-bound/recovery profile rather than an established uptrend. Entry-timing implication: wait for a reclaim of the 200-day or a pullback toward the 50-day; the current pattern does not scream oversold or overbought.

• A recovering hospital capital expenditure cycle is supporting imaging orders; Q2 book-to-bill of 1.15 and $23.9B backlog confirm the demand backdrop.
• Interest rate levels affect hospital borrowing costs and the timing of large multi-year equipment purchases.
• Inflation, tariffs, and supply chain friction are pressuring gross margins; TTM gross margin is only 42.9%.
• China remains a swing factor—policy, local competition, or geopolitical tension can hit a major regional market.
• AI-enabled diagnostics and recurring enterprise software revenue are structural tailwinds (110+ FDA AI authorizations).

• Wells Fargo 21st Annual Health Conference on September 9, 2026, where management may provide supply chain, Intelerad integration, and China demand updates.
• Conversion of the record $23.9B backlog into revenue and cash flow; Q2 orders +11.1% should show up in future quarters.
• Q3 2026 FCF/OCF normalization after Q2's seasonal -$617M FCF print would relieve the biggest fundamental concern.
• Potential upward consensus EPS revisions if margin/pricing actions offset tariff and inflation headwinds.

• Reported earnings are running ahead of cash: Q2 2026 FCF was -$617M and TTM FCF is only ~$895M, leaving the accrual ratio a caution flag.
• Leverage and liquidity: D/E 0.92, long-term debt $10.1B vs cash $2.1B, and current ratio only 1.02.
• China, tariffs, and hospital capex cyclicality could keep revenue and margins volatile; Q4 2025 revenue fell -12.1% YoY.
• Competitive and pricing pressure in imaging, ultrasound, and patient monitoring could limit operating margin upside.

GEHC is a quality healthcare franchise with strong orders and a reasonable forward multiple, but the realized financials are weak: TTM net margin ~7.9%, ROIC ~8.8%, negative Q2 FCF, and elevated debt. As of 2026-08-27 I would not buy at $72.48 without seeing the backlog convert into FCF; the score's weak-fundamental read and lack of valuation cushion skew risk/reward negative. This is analysis, not personalized advice.

Fair value calculated as 15.5x consensus next-FY EPS of $4.925 = $76.34. The 15.5x multiple is an ~11% discount to GEHC's 5-year average P/E of 17.5x to account for leverage, weak FCF conversion, and tariff/margin risk, while giving credit to the record backlog and mid-single-digit growth.